CALGARY, AB – Resverlogix Corp. has released preliminary results from its New Zealand-based Phase 1 trial using apabetalone (RVX-208) on severe kidney (renal) impaired patients.
According to a statement from the company, the data showed remarkable results in reducing inflamed protein biomarkers in patients with severe kidney impairment versus healthy control patients. The study points to a direct connection between epigenetic regulation and thus potential for positive disease impact.
Both the healthy group and the severely impaired kidney group received equal amounts of apabetalone.
“It was shocking and highly encouraging to see the direct comparison of the protein data ranked by magnitude of effect in the two groups,” stated Donald McCaffrey, president and CEO, Resverlogix. “For the first time, epigenetic and BET inhibition clinical data has been shown to differentially affect genes and proteins between advanced chronic kidney disease (CKD) patients and normal subjects.”
“These early results help provide a first understanding of the potential rapid effects of BET inhibition and apabetalone on key proteins that drive risk and death in Stage 4 CKD and potentially dialysis patients,” Dr. Kamyar Kalantar-Zadeh, chairman of the Renal clinical advisory board and member of the BETonMACE clinical steering committee stated. “Late Stage 4-5 CKD and dialysis patients represent very important groups whom currently have limited therapeutic strategies that can improve their outcomes and quality of life,” Dr. Kalantar-Zadeh added.
The company said that ongoing expanded analysis of this exploratory data is also planned which will look at Ingenuity Pathway Analysis (IPA). The quick onset of action and improvement of reported CKD risk factors are encouraging for the company in their planned expansion beyond its current cardiovascular and diabetes program. Detailed data will be submitted for peer reviewed publications.